Sera Prognostics, Inc. (SERA) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Sera Prognostics, Inc. (SERA) closed at USD 2.07 on 2026-10-14, a change of -44.8 % over the past year, with a market capitalization of USD 80.08M.

Sera Prognostics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sera Prognostics, Inc. key figures

Previous close

USD 2.07 (2026-10-14)

1-year change

-44.8 %

Market cap

USD 80.08M

Enterprise value

USD 36.64M

P/E ratio (trailing)

-3.03

P/E ratio (forward)

-3.79

EPS (trailing)

-0.67

EPS (forward)

-0.54

PEG ratio

n/a

Price to book

1.35

Revenue growth

76.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.40

Employees

71

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sera Prognostics, Inc.

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sera Prognostics, Inc. and compare it with other stocks.